安罗替尼治疗晚期非小细胞肺癌21例临床分析

Analysis of Anlotinib in the treatment of 21 cases with advanced non-small cell lung cancer

目的:分析安罗替尼在非小细胞肺癌(NSCLC)治疗中的应用效果。方法:选取2021年6月—2022年6月南京医科大学第二附属医院收治的21例晚期NSCLC患者,所有患者均使用安罗替尼或安罗替尼联合方案治疗,观察各种治疗方案的治疗效果及治疗相关不良反应。结果:21例患者中,使用安罗替尼联合方案18例,其中免疫检查点抑制剂联合安罗替尼12例(66.7%),靶向治疗联合安罗替尼5例(27.8%),化疗联合安罗替尼1例(5.6%);安罗替尼治疗3例。随访期间,共有10例出现病情进展(PD),7例患者病情稳定(SD),4例患者出现部分缓解(PR),总人群的中位无进展生存期(FPS)为6.32月。共8例出现了安罗替尼治疗相关不良反应(TRAEs),未出现治疗相关死亡。结论:安罗替尼联合治疗在晚期非小细胞中具疗效与安全性均较好,可作为治疗选择。

Objective To observe the efficacy of Anlotinib in advanced non-small cell lung cancer.Methods From June 2021 to June 2022,21 patients with advanced non-small cell lung cancer(NSCLC)who were admitted to the Second Affiliated Hospital of Nanjing Medical University were selected and treated with anlotinib or anlotinib combination regimen.The therapeutic effect and treatment-related adverse reactions were observed.Results Among the 21 patients,18 patients received Anlotinib combination regimen,including immune checkpoint inhibitor combined with anlotinib in 12 patients(66.7%),targeted therapy combined with anlotinib in 5 patients(27.8%).One case(5.6%)received chemotherapy combined with anlotinib.During the follow-up period,a total of 10 patients were assessed as progressive disease(PD),7 patients as stable disease(SD),and 4 patients as partial response(PR).The median progression-free survival(FPS)of the overall population was 6.32 months.A total of 8 patients experienced Anlotinib treatment-related adverse reactions(TRAEs),and no treatment-related deaths occurred.Conclusion Anlotinib combination therapy has good efficacy and safety in advanced non-small cell lung cancer,and can be used as a treatment option.